Infinity Pharmaceuticals AI Stock Analysis
Infinity Pharmaceuticals (INFIQ) AI Stock Analysis
Infinity Pharmaceuticals
(Other OTC:INFIQ)
No summary available
Infinity Pharmaceuticals (INFIQ) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $9,076
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- -112.19
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 30
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Infinity Pharmaceuticals Business Overview & Revenue Model
Company Description
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-on...
Infinity Pharmaceuticals Risk Analysis
Infinity Pharmaceuticals disclosed 76 risk factors in its most recent earnings report. Infinity Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksInfinity Pharmaceuticals Peers Comparison
Overall Rating
GOVX39Underperform
BMRA38Underperform
KALA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GOVX | 39Underperform | $32.67M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
| BMRA | 38Underperform | $6.81M | -0.93 | -142.81% | ― | -11.20% | -6.64% |
| KALA | 37Underperform | $3.31M | -0.00 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| INFIQ | Infinity Pharmaceuticals, Inc. | ― | ― | ― | |
| GOVX | Geovax Labs, Inc. | 2.16 | -279.24 | -99.23% | |
| BMRA | Biomerica Inc | 1.51 | -0.99 | -39.60% | |
| KALA | Kala Bio, Inc. | 0.17 | -32.73 | -99.48% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.